Compare CSGS & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGS | SRPT |
|---|---|---|
| Founded | 1994 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 1996 | 2000 |
| Metric | CSGS | SRPT |
|---|---|---|
| Price | $80.69 | $18.71 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 29 |
| Target Price | ★ $77.23 | $25.85 |
| AVG Volume (30 Days) | 308.4K | ★ 2.6M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.83 | ★ 2.88 |
| Revenue | $996,810,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $5.45 | N/A |
| Revenue Next Year | $3.02 | N/A |
| P/E Ratio | $97.23 | ★ $6.56 |
| Revenue Growth | 13.91 | ★ 15.58 |
| 52 Week Low | $60.54 | $10.42 |
| 52 Week High | $80.73 | $44.14 |
| Indicator | CSGS | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 38.51 |
| Support Level | $80.13 | $18.38 |
| Resistance Level | N/A | $19.62 |
| Average True Range (ATR) | 0.19 | 1.08 |
| MACD | 0.02 | -0.37 |
| Stochastic Oscillator | 93.62 | 1.76 |
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, it generates revenue from the United States.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.